Virus-induced immune dysregulation as a triggering factor for the development of drug rashes and autoimmune diseases: with emphasis on EB virus, human herpesvirus 6 and hepatitis C virus.
There are a considerable amount of empirical and theoretic medical literature regarding the possible role of viruses in the development of drug rashes and autoimmune diseases: under these conditions, interactions of viruses with the immune system would serve as an accelerating factor of disease pathogenesis. Recent reports have provided evidence to indicate that immune responses against infections with Epstein Barr (EB) virus and human herpesvirus 6 (HHV-6), which are lymphotropic members of the herpes virus group, not only aid the direct elimination of the virus but also contribute to a favorable milieu for the initiation or acceleration of drug rashes. Viruses that can persist for the lifetime of the host despite strong immune responses against them, such as EB virus and hepatitis C virus (HCV), would be also relevant to the pathogenesis of autoimmune diseases. HCV has been reportedly associated with a wide variety of dermatoses that, in common, show histologically the lichenoid tissue reaction. Although porokeratosis that manifests lichenoid histopathological features had long been regarded as being associated with immunosuppression, we found that HCV could act as trigger for the development of porokeratosis during states of immunosuppression. Thus, the main purpose of this review is to describe recent work on the etiology of drug rashes and autoimmune disease with special reference to viral infections.
Mizukawa
Y
Y
Department of Dermatology, Kyorin University School of Medicine, Mikata-city, Tokyo, Japan.
Shiohara
T
T
D001327:Autoimmune Diseases / Q000209:etiology*; D003875:Drug Eruptions / Q000209:etiology*; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000276:immunology; D016174:Hepacivirus / Q000472:pathogenicity*; D006526:Hepatitis C / Q000150:complications / Q000276:immunology; D006566:Herpesviridae Infections / Q000150:complications / Q000276:immunology; D004854:Herpesvirus 4, Human / Q000472:pathogenicity*; D015654:Herpesvirus 6, Human / Q000472:pathogenicity*; D006801:Humans; D017499:Porokeratosis / Q000209:etiology